<DOC>
	<DOCNO>NCT01960790</DOCNO>
	<brief_summary>This investigation conduct obtain follow information regard use Adalimumab 40mg Syringe 0.8mL Subcutaneous Injection patient Intestinal Behcet 's Disease . 1 . Incidence condition occurrence adverse reaction clinical practice 2 . Factors likely affect safety effectiveness</brief_summary>
	<brief_title>Special Investigation Patients With Intestinal Behcet 's Disease ( All Case Investigation )</brief_title>
	<detailed_description />
	<mesh_term>Behcet Syndrome</mesh_term>
	<criteria>All patient receive Adalimumab treatment Intestinal Behcet 's disease ( sufficiently responsive exist therapy , e.g . steroid , immunomodulator ) Contraindications accord Package Insert include patient follow : serious infection tuberculosis history hypersensitivity ingredient Humira® demyelinate disease history demyelinate disease congestive cardiac failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Humira®</keyword>
	<keyword>Behcet 's Disease</keyword>
	<keyword>Adalimumab</keyword>
</DOC>